TOP-N-53

N/A

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameTOP-N-53
Drug Alias NameTOP-N53TOP-N53TOP-N73c
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNitric oxide donorsSoluble guanylate cyclase stimulantsPhosphodiesterase 5A inhibitors
TargetsSoluble guanylate cyclasePhosphodiesterase 5A
Therapy Area/IndicationsSkin UlcerScleroderma, SystemicDiabetic Foot
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerlandFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTopadur Pharma AG
China Registration ClassN/A

Develop Information

Active CompaniesJuvic IncYonsei UniversityTopadur Pharma AG
Inactive CompaniesN/A
Active IndicationsSkin UlcerScleroderma, SystemicDiabetic Foot
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A